Literature DB >> 11468294

Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction.

C Haan1, H Is'harc, H M Hermanns, H Schmitz-Van De Leur, I M Kerr, P C Heinrich, J Grötzinger, I Behrmann.   

Abstract

Janus kinase 1 (Jak1) is a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors. Here we show that the in vitro translated N-terminal domains of Jak1 are sufficient for binding to a biotinylated peptide comprising the membrane-proximal 73 amino acids of gp130, the signal-transducing receptor chain of interleukin-6-type cytokines. By the fold recognition approach amino acid residues 36-112 of Jak1 were predicted to adopt a beta-grasp fold, and a structural model was built using ubiquitin as a template. Substitution of Tyr(107) to alanine, a residue conserved among Jaks and involved in hydrophobic core interactions of the proposed beta-grasp domain, abrogated binding of full-length Jak1 to gp130 in COS-7 transfectants. By further mutagenesis we identified the loop 4 region of the Jak1 beta-grasp domain as essential for gp130 association and gp130-mediated signal transduction. In Jak1-deficient U4C cells reconstituted with the loop 4 Jak1 mutants L80A/Y81A and Delta(Tyr(81)-Ser(84)), the interferon-gamma, interferon-alpha, and interleukin-6 responses were similarly impaired. Thus, loop 4 of the beta-grasp domain plays a role in the association of Jak1 with both class I and II cytokine receptors. Taken together the structural model and the mutagenesis data provide further insight into the interaction of Janus kinases with cytokine receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468294     DOI: 10.1074/jbc.M106135200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation.

Authors:  Claude Haan; Peter C Heinrich; Iris Behrmann
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

Review 2.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

3.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

Review 4.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

5.  Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.

Authors:  Tekla Hornakova; Lorraine Springuel; Julien Devreux; Alexandra Dusa; Stefan N Constantinescu; Laurent Knoops; Jean-Christophe Renauld
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

6.  Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Authors:  Sigrun R Hofmann; Albert Q Lam; Stephan Frank; Yong-Jie Zhou; Haydeé L Ramos; Yuka Kanno; Davide Agnello; Richard J Youle; John J O'Shea
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 7.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

8.  Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Authors:  Tekla Hornakova; Judith Staerk; Yohan Royer; Elisabetta Flex; Marco Tartaglia; Stefan N Constantinescu; Laurent Knoops; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

9.  Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Authors:  Elisabeth Losdyck; Tekla Hornakova; Lorraine Springuel; Sandrine Degryse; Olga Gielen; Jan Cools; Stefan N Constantinescu; Elisabetta Flex; Marco Tartaglia; Jean-Christophe Renauld; Laurent Knoops
Journal:  J Biol Chem       Date:  2015-10-07       Impact factor: 5.157

10.  Classification of nonenzymatic homologues of protein kinases.

Authors:  K Anamika; K R Abhinandan; K Deshmukh; N Srinivasan
Journal:  Comp Funct Genomics       Date:  2009-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.